| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.29▲ | 1.29▲ | 1.29▲ | 1.59▼ | 1.81▼ |
| MA10 | 1.24▲ | 1.34▼ | 1.41▼ | 1.69▼ | 2.35▼ |
| MA20 | 1.36▼ | 1.51▼ | 1.56▼ | 1.85▼ | 2.38▼ |
| MA50 | 1.57▼ | 1.66▼ | 1.71▼ | 2.40▼ | 2.44▼ |
| MA100 | 1.74▼ | 1.85▼ | 1.88▼ | 2.39▼ | 3.68▼ |
| MA200 | 1.91▼ | 2.27▼ | 2.38▼ | 2.50▼ | 30.95▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.012▲ | -0.019▼ | -0.028▼ | -0.020▼ | -0.129▼ |
| RSI | 44.197▼ | 39.735▼ | 28.179▼ | 23.135▼ | 33.790▼ |
| STOCH | 78.475 | 42.429 | 39.714 | 19.418▼ | 8.723▼ |
| WILL %R | -22.552▲ | -50.303 | -50.303 | -66.957 | -86.851▼ |
| CCI | 32.901 | -49.713 | -71.254 | -273.156▼ | -153.692▼ |
|
Thursday, August 14, 2025 05:17 PM
GTB-3650 TriKE ® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and ...
|
|
Monday, August 11, 2025 04:11 AM
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues ...
|
|
Tuesday, July 01, 2025 09:08 AM
Nasdaq handily beat the New York Stock Exchange in stock market listings during the first half of 2025, buoyed by blockbuster initial public offerings of big names like CoreWeave and Chime and a ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 1.46 | 1.46 | 0.96 | 1.34 | 263,681 |
| 14/08/25 | 1.68 | 1.70 | 1.38 | 1.45 | 132,604 |
| 13/08/25 | 1.70 | 1.735 | 1.68 | 1.68 | 38,889 |
| 12/08/25 | 1.77 | 1.77 | 1.68 | 1.7494 | 57,296 |
| 11/08/25 | 1.74 | 1.7799 | 1.71 | 1.74 | 45,018 |
| 08/08/25 | 1.89 | 1.89 | 1.74 | 1.79 | 26,600 |
| 07/08/25 | 1.77 | 1.83 | 1.68 | 1.83 | 33,318 |
| 06/08/25 | 1.77 | 1.8357 | 1.72 | 1.74 | 98,711 |
| 05/08/25 | 1.77 | 1.78 | 1.72 | 1.77 | 41,526 |
| 04/08/25 | 1.81 | 1.85 | 1.76 | 1.78 | 54,848 |
|
|
||||
|
|
||||
|
|